Have sufficient Amphotericin B stock for treating Black Fungus cases: Govt
The Ministry of Chemicals and Fertilizers on Friday said India has more than sufficient stock of Liposomal Amphotericin B drug for the treatment of Mucormycosis.
Minister of State Mansukh Mandaviya said: “Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers has allocated a total 7,28,045 vials of Liposomal Amphotericin B to all the states and Central institutions till June 17, 2021.”
The Ministry said, on June 16 active cases of Mucormycosis were 27,142.
Even in the future, if cases of Black Fungus increases, India is prepared to have more than sufficient availability of Amphotericin B drug and other drugs which are required to treat patients of Mucormycosis.
India has increased domestic production remarkably by more than fivefold. Domestic production of Liposomal Amphotericin B was just 62,000 vials in April, 2021 and now it is expected to cross 3.75 lakh vials in June, 2021.
While increasing domestic production, India also placed order to import 9,05,000 Liposomal Amphotericin Bvials through M/s Mylan.
India is leaving no stone unturned to boost the availability of Amphotericin B drugs in the country,” said Mandaviya.
Amphotericin B drug is used for the treatment of Mucormycosis, commonly known as Black Fungus.
–IANS
miz/in
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
